Susquehanna International Group
FATE icon

Susquehanna International Group’s Fate Therapeutics FATE Stock Holding History

Susquehanna International Group’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$60.6K Buy
+50,500
New +$61.5K ﹤0.01% 12578
2025
Q3 		– Sell
-98,300
Closed -$110K – 12790
2025
Q2 		$110K Buy
+98,300
New +$114K ﹤0.01% 11732
2025
Q1 		– Sell
-25,500
Closed -$42.1K – 12744
2024
Q4 		$42.1K Buy
+25,500
New +$64.3K ﹤0.01% 11747
2024
Q3 		– Sell
-11,900
Closed -$39K – 12258
2024
Q2 		$39K Sell
11,900
-49,200
-81% -$215K ﹤0.01% 11501
2024
Q1 		$448K Buy
+61,100
New +$378K ﹤0.01% 8772
2023
Q1 		– Sell
-28,000
Closed -$283K – 12813
2022
Q4 		$283K Buy
28,000
+7,100
+34% +$133K ﹤0.01% 9240
2022
Q3 		$468K Buy
20,900
+6,200
+42% +$179K ﹤0.01% 8673
2022
Q2 		$364K Sell
14,700
-35,700
-71% -$985K ﹤0.01% 9030
2022
Q1 		$1.95M Buy
50,400
+21,200
+73% +$821K ﹤0.01% 5532
2021
Q4 		$1.71M Sell
29,200
-11,800
-29% -$669K ﹤0.01% 5890
2021
Q3 		$2.43M Sell
41,000
-29,000
-41% -$2.27M ﹤0.01% 5416
2021
Q2 		$6.08M Sell
70,000
-42,400
-38% -$3.42M ﹤0.01% 3668
2021
Q1 		$9.27M Buy
112,400
+61,300
+120% +$5.87M ﹤0.01% 2890
2020
Q4 		$4.65M Buy
51,100
+4,400
+9% +$273K ﹤0.01% 3522
2020
Q3 		$1.87M Sell
46,700
-26,000
-36% -$908K ﹤0.01% 4755
2020
Q2 		$2.49M Sell
72,700
-40,400
-36% -$1.2M ﹤0.01% 4104
2020
Q1 		$2.51M Sell
113,100
-47,800
-30% -$1.21M ﹤0.01% 3570
2019
Q4 		$3.15M Sell
160,900
-16,800
-9% -$267K ﹤0.01% 3631
2019
Q3 		$2.76M Sell
177,700
-97,600
-35% -$1.87M ﹤0.01% 3629
2019
Q2 		$5.59M Buy
275,300
+76,300
+38% +$1.37M ﹤0.01% 2570
2019
Q1 		$3.5M Buy
199,000
+54,600
+38% +$862K ﹤0.01% 2924
2018
Q4 		$1.85M Buy
144,400
+46,400
+47% +$647K ﹤0.01% 3635
2018
Q3 		$1.6M Buy
98,000
+61,600
+169% +$728K ﹤0.01% 4363
2018
Q2 		$413K Sell
36,400
-9,900
-21% -$109K ﹤0.01% 7187
2018
Q1 		$452K Buy
+46,300
New +$444K ﹤0.01% 6839

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group's FATE Position: Q1 2026 in Review

Susquehanna International Group reduced its Fate Therapeutics (FATE) stake by 3.8% in Q1 2026, selling an estimated $14.2K and leaving 298,496 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #10473.

Susquehanna International Group first reported a position in FATE in Q4 2017 and has held it in 31 quarters since. The position peaked at $6.44M in Q4 2020. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Susquehanna International Group held 298,496 shares of Fate Therapeutics worth $358K as of Q1 2026.
  • Susquehanna International Group sold 11,695 Fate Therapeutics shares in Q1 2026, an estimated $14.2K.
  • Fate Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #10473 holding.
  • Susquehanna International Group first reported a position in Fate Therapeutics in Q4 2017 and has held it in 31 quarters since.
  • Susquehanna International Group's Fate Therapeutics position peaked at $6.44M in Q4 2020.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.